{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T08:38:39Z","timestamp":1778661519691,"version":"3.51.4"},"reference-count":14,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T00:00:00Z","timestamp":1632268800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Bevacizumab is a recombinant humanized monoclonal antibody and a key drug for treatment of various types of cancer. Bevacizumab is associated with the occurrence of heart failure, but its risk factors remain unknown. A 55-year-old woman was diagnosed with cervical cancer, which was completely treated by bevacizumab-incorporated chemotherapy. During the 9-month bevacizumab therapy, she suffered from hypertension requiring multiple antihypertensive agents. She was admitted to our hospital due to acute heart failure with afterload mismatch and severe mitral regurgitation. A transesophageal echocardiography showed Barlow\u2019s disease with a degenerated and widely prolapsed mitral valve. She received a scheduled surgical mitral valve repair. Post-operative cause was uneventful, but metastatic dissemination developed later. The existence of mitral valve regurgitation, even when sub-clinical, might be a risk of worsening heart failure during bevacizumab therapy. Careful follow-up at an onco-cardiology clinic is highly encouraged particularly for such a cohort during bevacizumab therapy.<\/jats:p>","DOI":"10.3390\/medicina57100998","type":"journal-article","created":{"date-parts":[[2021,9,26]],"date-time":"2021-09-26T22:24:13Z","timestamp":1632695053000},"page":"998","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Acute Heart Failure in a Patient with Occult Barlow\u2019s Disease Receiving Bevacizumab"],"prefix":"10.3390","volume":"57","author":[{"given":"Toshihide","family":"Izumida","sequence":"first","affiliation":[{"name":"Second Department of Medicine, University of Toyama, Toyama 930-0194, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7294-7637","authenticated-orcid":false,"given":"Teruhiko","family":"Imamura","sequence":"additional","affiliation":[{"name":"Second Department of Medicine, University of Toyama, Toyama 930-0194, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohei","family":"Ueno","sequence":"additional","affiliation":[{"name":"Second Department of Medicine, University of Toyama, Toyama 930-0194, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuaki","family":"Fukahara","sequence":"additional","affiliation":[{"name":"Department of Surgery 1, Faculty of Medicine, University of Toyama, Toyama 930-0194, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichiro","family":"Kinugawa","sequence":"additional","affiliation":[{"name":"Second Department of Medicine, University of Toyama, Toyama 930-0194, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/ejhf.1165","article-title":"Cancer diagnosis in patients with heart failure: Epidemiology, clinical implications and gaps in knowledge","volume":"20","author":"Ameri","year":"2018","journal-title":"Eur. J. Heart Fail."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/978-1-62703-586-6_4","article-title":"Therapeutic human monoclonal antibodies against cancer","volume":"1060","author":"Jarboe","year":"2014","journal-title":"Methods Mol. Biol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.pharmthera.2017.08.012","article-title":"Bevacizumab-induced hypertension: Clinical presentation and molecular understanding","volume":"182","author":"Li","year":"2018","journal-title":"Pharmacol Ther."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"van Wijngaarden, A.L., Kruithof, B.P.T., Vinella, T., Barge-Schaapveld, D.Q.C.M., and Ajmone Marsan, N. (2021). Characterization of Degenerative Mitral Valve Disease: Differences between Fibroelastic Deficiency and Barlow\u2019s Disease. J. Cardiovasc. Dev. Dis., 8.","DOI":"10.3390\/jcdd8020023"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e006278","DOI":"10.1161\/JAHA.117.006278","article-title":"Cardiovascular Adverse Events in Patients with Cancer Treated with Bevacizumab: A Meta-Analysis of More Than 20,000 Patients","volume":"6","author":"Totzeck","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ctrv.2016.12.002","article-title":"Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis","volume":"53","author":"Ethier","year":"2017","journal-title":"Cancer Treat Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1200\/JCO.2010.31.9129","article-title":"Congestive heart failure risk in patients with breast cancer treated with bevacizumab","volume":"29","author":"Choueiri","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1093\/annonc\/mdt019","article-title":"Bevacizumab use and risk of cardiovascular adverse events among elderly patients with colorectal cancer receiving chemotherapy: A population-based study","volume":"24","author":"Tsai","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11936-017-0550-6","article-title":"Valvular Heart Disease in Cancer Patients: Etiology, Diagnosis, and Management","volume":"19","author":"Stewart","year":"2017","journal-title":"Curr. Treat. Options Cardiovasc. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.vph.2018.10.007","article-title":"Arterial stiffness and mitral regurgitation in arterial hypertension: An intriguing pathophysiological link","volume":"111","author":"Imbalzano","year":"2018","journal-title":"Vascul. Pharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s12012-020-09583-5","article-title":"Speckle-Tracking Echocardiography for Cardioncological Evaluation in Bevacizumab-Treated Colorectal Cancer Patients","volume":"20","author":"Sonaglioni","year":"2020","journal-title":"Cardiovasc. Toxicol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.echo.2018.09.019","article-title":"Echocardiographic Assessment for the Detection of Cardiotoxicity Due to Vascular Endothelial Growth Factor Inhibitor Therapy in Metastatic Renal Cell and Colorectal Cancers","volume":"32","author":"Nhola","year":"2019","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jacbts.2021.05.008","article-title":"Cardio-Oncology: Understanding the Intersections Between Cardiac Metabolism and Cancer Biology","volume":"6","author":"Karlstaedt","year":"2021","journal-title":"JACC Basic Transl. Sci."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/57\/10\/998\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:03:16Z","timestamp":1760166196000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/57\/10\/998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,22]]},"references-count":14,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["medicina57100998"],"URL":"https:\/\/doi.org\/10.3390\/medicina57100998","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,22]]}}}